中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Metabolic Diseases
Immune Diseases
Exploratory Indications
Pipeline
Pipeline
Clinical Trials
Partnership
Investors
Financials & Filing
Upcoming Events
Corporate presentation
SCIENTIFIC PRESENTATIONS
News
Careers
Investors
Financials & Filing
Upcoming Events
Corporate presentation
SCIENTIFIC PRESENTATIONS
2026
2025
2024
2023
2022
2021
2020
2019
2018
2026
2025
2024
2023
2022
2021
2020
2019
2018
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
2026-02-03
Placing of New Shares under the General Mandate
2026-02-03
Voluntary Announcement - Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
2026-01-29
Voluntary Announcement - Ascletis Announces First Participants Dosed in a 13-Week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
2026-01-26
Voluntary Announcement - Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
2026-01-20
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
2026-01-05
Voluntary Announcement - Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
2026-01-05
浙公网安备 33010802003344号
浙ICP备11050387号-1